The first single-dose flu drug nod could be FDA’s Christmas present for Roche

26th June 2018 Uncategorised 0

The U.S. hasn’t had a new class of antivirals approved for influenza in over 20 years. Now, an FDA priority review granted to Shionogi and Roche’s baloxavir marboxil could change that before New Year’s.

More: The first single-dose flu drug nod could be FDA’s Christmas present for Roche
Source: fierce